JNJ / Johnson & Johnson - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 29, 2025 ☐ Transition Report Pursuant to S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 29, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact

SECOND QUARTER % Change 2025 2024 Reported Operational(1) Currency INNOVATIVE MEDICINE SEGMENT(2) ONCOLOGY US $3,385 2,636 28.4 % 28.4 % — % Intl 2,928 2,455 19.3 15.7 3.6 WW 6,312 5,090 24.0 22.3 1.7 CARVYKTI US 358 167 * * — Intl 81 20 * * * WW 439

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change Sales to customers by geographic area 2025 2024 Total Operations Currency U.S. $13,544 12,569 7.8 % 7.8 — Europe 5,387 5,214 3.3 (1.9) 5.2 Western Hemisphere excluding U.S. 1,206 1,212 (0.5) 6.2 (6.7) Asia-Pacific, Africa 3,606 3,452 4.4 2.4 2.0 International 10,1

% Change

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For immediate release Johnson & Johnson reports Q2 2025 results; raises 2025 outlook •2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* •2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2025 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] FOR IMMEDIATE RELEASE Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors New Brunswick, New Jersey (June 10, 2025) – Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson Johnson & Johnson (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson Johnson & Johnson (Exact Name of Registrant as Specified in Charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Addr

Exhibit 1.01

Exhibit 1.01 Johnson & Johnson Conflict Minerals Report For the Calendar Year Ended December 31, 2024 Introduction Johnson & Johnson is the parent company of various consolidated subsidiaries (together, the “Company”) engaged in the manufacture and sale of a broad range of Innovative Medicine and MedTech products in the healthcare field. Pursuant to the requirements of Rule 13p-1 under the Securit

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

2

Joseph J. Wolk Executive Vice President Chief Financial Officer Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08893 April 23, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Re: Johnson & Johnson Form 10-K for the Fiscal Year Ended December 29, 2024 File No. 001-03215 Dear Mr. Atallah and Mr. Gordon: Johnson &

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2025 ☐ Transition Report Pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact

Notice of Exempt Solicitation Pursuant to Rule 14a-103 | April 23, 2025

Notice of Exempt Solicitation Pursuant to Rule 14a-103 | April 23, 2025 Name of Registrant: Johnson & Johnson Name of person relying on exemption: Bowyer Research Address of person relying on exemption: P.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

% Change

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For immediate release Johnson & Johnson reports Q1 2025 results •2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* •2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversa

FIRST QUARTER % Change 2025 2024 Reported Operational(1) Currency INNOVATIVE MEDICINE SEGMENT(2) ONCOLOGY US $3,013 2,383 26.4 % 26.4 % — % Intl 2,664 2,430 9.6 14.4 (4.8) WW 5,678 4,814 17.9 20.4 (2.5) CARVYKTI US 318 140 * * — Intl 51 16 * * * WW 3

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change Sales to customers by geographic area 2025 2024 Total Operations Currency U.S. $12,305 11,620 5.9 % 5.9 — Europe 5,110 5,163 (1.0) 2.2 (3.2) Western Hemisphere excluding U.S. 1,167 1,194 (2.3) 9.2 (11.5) Asia-Pacific, Africa 3,311 3,406 (2.8) (0.6) (2.2) Internatio

Johnson & Johnson Announces 63

Exhibit 99.3 Media contact: [email protected] Investor contact: [email protected] Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8% New Brunswick, NJ (April 15, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share t

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For Immediate Release Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution NEW BRUNSWICK,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 Johnson & Johnson (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

This is not a solicitation of authority to vote your proxy.ac1300 Please DO NOT send us your proxy card as it will not be accepted

Notice of Exempt Solicitation NAME OF REGISTRANT: Johnson & Johnson NAME OF PERSON RELYING ON EXEMPTION: Mercy Investment Services ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N Geyer Rd, Frontenac, MO 63131 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Form of 3.050% Notes due 2033.

Exhibit 4.3 CUSIP NO.: 478160 DC5 ISIN: XS3005214369 Common Code: 300521436 PRINCIPAL AMOUNT €[    ] REGISTERED NO. R- JOHNSON & JOHNSON 3.050% NOTE DUE 2033 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payme

Form of 3.600% Notes due 2045.

Exhibit 4.5 CUSIP NO.: 478160 DE1 ISIN: XS3005215093 Common Code: 300521509 PRINCIPAL AMOUNT   €[    ] REGISTERED NO. R- JOHNSON & JOHNSON 3.600% NOTE DUE 2045 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or pay

Form of 3.350% Notes due 2037.

Exhibit 4.4 CUSIP NO.: 478160 DD3 ISIN: XS3005214799 Common Code: 300521479 PRINCIPAL AMOUNT   €[    ] REGISTERED NO. R- JOHNSON & JOHNSON 3.350% NOTE DUE 2037 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or pay

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Form of 3.700% Notes due 2055.

Exhibit 4.6 CUSIP NO.: 478160 DF8 ISIN: XS3005215689 Common Code: 300521568 PRINCIPAL AMOUNT   €[    ] REGISTERED NO. R- JOHNSON & JOHNSON 3.700% NOTE DUE 2055 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or pay

Underwriting Agreement, dated February 19, 2025, among Johnson & Johnson and Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC and the several Underwriters named therein.

Exhibit 1.1 UNDERWRITING AGREEMENT February 19, 2025 New York, New York Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: Citigroup Global Markets Limited Citigroup Centre Canada Square Canary Wharf London E14 5LB United Kingdom Deutsche Bank AG, London Branch 21 Moorfields London EC2Y 9DB United Kingdom Goldman Sachs & Co. LLC 200 West Street New York, New Y

Form of 2.700% Notes due 2029.

Exhibit 4.2 CUSIP NO.: 478160 DB7 ISIN: XS3005214104 Common Code: 300521410 PRINCIPAL AMOUNT   €[    ] REGISTERED NO. R- JOHNSON & JOHNSON 2.700% NOTE DUE 2029 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or pay

Company Order establishing the terms of the Notes.

Exhibit 4.1 JOHNSON & JOHNSON COMPANY ORDER Pursuant to the authorization of the Board of Directors of Johnson & Johnson, a New Jersey corporation (the “Company”), in resolutions adopted on February 14, 2023, October 31, 2022 and April 25, 2024, the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of the Company, with the terms and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Johnson & Johnson (Exact Name of Registrant as

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Johnson & Johnson (Exact Name of Registrant as Specified in Its Charter) New Jersey 22-1024240 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Calculation of Filing Fee Tables (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security  Class Title  Fee Calculation  or Carry  Forward Rule  Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be  Paid  Debt  2.

€600,000,000 2.700% Notes due 2029 €700,000,000 3.050% Notes due 2033 €1,000,000,000 3.350% Notes due 2037 €700,000,000 3.600% Notes due 2045 €1,000,000,000 3.700% Notes due 2055

Table of Contents Filed Pursuant to Rule 424(b)(2) File number 333-269836 PROSPECTUS SUPPLEMENT (To Prospectus dated February 16, 2023) €600,000,000 2.

Underwriting Agreement Standard Provisions (Debt) dated February 18, 2025.

Exhibit 1.2 JOHNSON & JOHNSON UNDERWRITING AGREEMENT STANDARD PROVISIONS (DEBT) February 18, 2025 From time to time, Johnson & Johnson, a New Jersey corporation (the “Company”), may enter into one or more underwriting agreements (each, an “Underwriting Agreement”) that provide for the sale of designated securities to the several underwriters named therein (the “Underwriters”) arranged by the manag

Company Order establishing the terms of the Notes.

Exhibit 4.1 JOHNSON & JOHNSON COMPANY ORDER Pursuant to the authorization of the Board of Directors of Johnson & Johnson, a New Jersey corporation (the “Company”), in resolutions adopted on February 14, 2023, October 31, 2022 and April 25, 2024, the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of the Company, with the terms and

Underwriting Agreement, dated February 18, 2025, among Johnson & Johnson and Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC, as representatives of the several Underwriters named therein.

Exhibit 1.1 UNDERWRITING AGREEMENT February 18, 2025 New York, New York Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 BofA Securities, Inc. One Bryant Park New York, New York 10036 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Citigro

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Form of 4.550% Notes due 2028.

Exhibit 4.3 CUSIP NO. 478160 DH4 PRINCIPAL AMOUNT $[    ] REGISTERED NO. R- JOHNSON & JOHNSON 4.550% NOTE DUE 2028 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CEDE & CO.,

Form of 5.000% Notes due 2035.

Exhibit 4.6 CUSIP NO. 478160 DL5 PRINCIPAL AMOUNT $[    ] REGISTERED NO. R- JOHNSON & JOHNSON 5.000% NOTE DUE 2035 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CEDE & CO.,

Form of 4.700% Notes due 2030.

Exhibit 4.4 CUSIP NO. 478160 DJ0 PRINCIPAL AMOUNT $[    ] REGISTERED NO. R- JOHNSON & JOHNSON 4.700% NOTE DUE 2030 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CEDE & CO.,

Form of 4.850% Notes due 2032.

Exhibit 4.5 CUSIP NO. 478160 DK7 PRINCIPAL AMOUNT    $[    ] REGISTERED NO. R- JOHNSON & JOHNSON 4.850% NOTE DUE 2032 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CEDE & C

Form of 4.500% Notes due 2027.

Exhibit 4.2 CUSIP NO. 478160 DG6 PRINCIPAL AMOUNT    $[    ] REGISTERED NO. R- JOHNSON & JOHNSON 4.500% NOTE DUE 2027 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CEDE & C

Pricing Term Sheet Johnson & Johnson 2.700% Notes due 2029 3.050% Notes due 2033 3.350% Notes due 2037 3.600% Notes due 2045 3.700% Notes due 2055 Issuer: Johnson & Johnson Trade Date: February 19, 2025 Expected Settlement Date:* February 26, 2025 (T

FWP 1 d900883dfwp.htm FWP Filed Pursuant to Rule 433 Registration No. 333-269836 February 19, 2025 Pricing Term Sheet Johnson & Johnson 2.700% Notes due 2029 3.050% Notes due 2033 3.350% Notes due 2037 3.600% Notes due 2045 3.700% Notes due 2055 Issuer: Johnson & Johnson Trade Date: February 19, 2025 Expected Settlement Date:* February 26, 2025 (T+5) Format: SEC Registered Security: 2.700% Notes d

Calculation of Filing Fee Tables (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type Security Class Title  Fee Calculation or Carry Forward Rule Amount Registered  Proposed Maximum Offering Price Per Unit  Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Debt 4.

Subject to Completion, dated February 19, 2025

Table of Contents Filed Pursuant to Rule 424(b)(5) File number 333-269836 The information in this preliminary prospectus supplement is not complete and may be changed.

$750,000,000 4.500% Notes due 2027 $750,000,000 4.550% Notes due 2028 $1,000,000,000 4.700% Notes due 2030 $1,250,000,000 4.850% Notes due 2032 $1,250,000,000 5.000% Notes due 2035

Table of Contents Filed Pursuant to Rule 424(b)(2) File number 333-269836 PROSPECTUS SUPPLEMENT (To Prospectus dated February 16, 2023) $750,000,000 4.

Pricing Term Sheet Johnson & Johnson 4.500% Notes due 2027 4.550% Notes due 2028 4.700% Notes due 2030 4.850% Notes due 2032 5.000% Notes due 2035 Issuer: Johnson & Johnson (the “Company”) Security: 4.500% Notes due 2027 4.550% Notes due 2028 4.700%

Filed Pursuant to Rule 433 Registration No. 333-269836 February 18, 2025 Pricing Term Sheet Johnson & Johnson 4.500% Notes due 2027 4.550% Notes due 2028 4.700% Notes due 2030 4.850% Notes due 2032 5.000% Notes due 2035 Issuer: Johnson & Johnson (the “Company”) Security: 4.500% Notes due 2027 4.550% Notes due 2028 4.700% Notes due 2030 4.850% Notes due 2032 5.000% Notes due 2035 Size: $750,000,000

Subject to Completion, dated February 18, 2025

Table of Contents Filed Pursuant to Rule 424(b)(5) File number 333-269836 The information in this preliminary prospectus supplement is not complete and may be changed.

JOHNSON & JOHNSON EXECUTIVE OFFICER CASH SEVERANCE POLICY

Exhibit 10(ab) JOHNSON & JOHNSON EXECUTIVE OFFICER CASH SEVERANCE POLICY Johnson & Johnson (the “Company”) will not enter into any new employment agreement, severance agreement or separation agreement with any Executive Officer of the Company, or establish any new severance plan or policy covering any Executive Officer of the Company, in each case that provides for Cash Severance Benefits exceeding 2.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2024 ☐ Transition Report Pursuant to Section 13 or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of regis

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Description of Capital Stock

Exhibit 4(b) DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Description of Capital Stock The following summary of the capital stock of Johnson & Johnson (“we,” “us” or “our”) does not purport to be complete and is subject in all respects to applicable New Jersey law, the Johnson & Johnson restated certificate of incorporation, as amended, and the Johnson & Johnson by-laws.

Name of Subsidiary Jurisdiction U.S. Subsidiaries: ABD Holding Company, Inc. Delaware ABIOMED COMMERCIAL, LLC Delaware ABIOMED R&D, Inc. Delaware ABIOMED, Inc. Delaware Actelion Pharmaceuticals US, Inc. Delaware Albany Street LLC New Jersey ALZA Corp

EXHIBIT 21 SUBSIDIARIES Johnson & Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of December 29, 2024. Johnson & Johnson is not a subsidiary of any other entity. Name of Subsidiary Jurisdiction U.S. Subsidiaries: ABD Holding Company, Inc. Delaware ABIOMED COMMERCIAL, LLC Delaware ABIOMED R&D, Inc. Delaware ABIOMED, Inc. Delaware Actelion Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Full Year

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For immediate release Johnson & Johnson reports Q4 and Full-Year 2024 results •2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* •2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of

Full Year

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For immediate release Johnson & Johnson reports Q4 and Full-Year 2024 results •2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* •2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of

FOURTH QUARTER % Change 2024 2023 Reported Operational(1) Currency INNOVATIVE MEDICINE SEGMENT(2) IMMUNOLOGY US $2,856 3,033 (5.9) % (5.9) % — % Intl 1,383 1,562 (11.5) (6.5) (5.0) WW 4,238 4,595 (7.8) (6.1) (1.7) REMICADE US 231 294 (21.4) (21.4) —

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) FOURTH QUARTER Percent Change Sales to customers by geographic area 2024 2023 Total Operations Currency U.S. $13,204 12,009 10.0 % 10.0 — Europe 4,921 4,962 (0.8) (0.2) (0.6) Western Hemisphere excluding U.S. 1,135 1,166 (2.7) 17.6 (20.3) Asia-Pacific, Africa 3,260 3,258 0.1 0.9 (0.8) Internat

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2025 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 18, 2024, pursuant to the provisions of Rule 12d2-2 (a).

CVRX / CVRx, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 s13ga093024-cvrx.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 CVRx, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 29, 2024 ☐ Transition Report Pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 29, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (E

RAPP / Rapport Therapeutics, Inc. / JOHNSON & JOHNSON Passive Investment

SC 13G 1 s13g093024-rapportthera.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Rapport Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 75383L102 (C

MGTX / MeiraGTx Holdings plc / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 s13g101524-meiragtx.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 MeiraGTx Holdings plc (Name of Issuer) Ordinary Shares, $.00003881 par value (Title of Class of Securiti

Press Release

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] Johnson & Johnson reports Q3 2024 results •2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* •2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and a

THIRD QUARTER % Change 2024 2023 Reported Operational(1) Currency INNOVATIVE MEDICINE SEGMENT(2) IMMUNOLOGY US $3,068 3,193 (3.9) % (3.9) % — % Intl 1,552 1,656 (6.2) (2.1) (4.1) WW 4,621 4,849 (4.7) (3.3) (1.4) REMICADE US 281 296 (5.4) (5.4) — US E

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) THIRD QUARTER Percent Change Sales to customers by geographic area 2024 2023 Total Operations Currency U.S. $12,909 11,996 7.6 % 7.6 — Europe 4,914 4,727 4.0 3.0 1.0 Western Hemisphere excluding U.S. 1,173 1,171 0.3 20.3 (20.0) Asia-Pacific, Africa 3,475 3,457 0.5 1.5 (1.0) International 9,562

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2024 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims

Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For Immediate Release Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims Approximately 83% of Current Claimants and the Future Claims Representative Support the Propo

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Joshina Kapoor

Exhibit 99.1 Media contact: Joshina Kapoor [email protected] For immediate release Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 NEW BRUNSWICK, N.J. (August 26, 2024) - Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter M. Fasolo will retire fr

RLYB / Rallybio Corporation / JOHNSON & JOHNSON Passive Investment

SC 13G 1 rallybiosch13gforjjdc.htm CUSIP No. 72120L100 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )[1] Rallybio Corporation (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 ☐ Transition Report Pursuant to S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact

SECOND QUARTER % Change 2024 2023 Reported Operational(1) Currency INNOVATIVE MEDICINE SEGMENT(2) IMMUNOLOGY US $2,978 2,865 4.0 % 4.0 % — % Intl 1,744 1,631 6.9 13.2 (6.3) WW 4,722 4,496 5.0 7.3 (2.3) REMICADE US 231 277 (16.7) (16.7) — US Exports(3

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change Sales to customers by geographic area 2024 2023 Total Operations Currency U.S. $12,569 11,657 7.8 % 7.8 — Europe 5,214 5,131 1.6 3.4 (1.8) Western Hemisphere excluding U.S. 1,212 1,136 6.7 22.6 (15.9) Asia-Pacific, Africa 3,452 3,595 (4.0) 1.9 (5.9) International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Press Release

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] Johnson & Johnson reports Q2 2024 results •2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* •2024 Second-Quar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K/A FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K/A FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson Johnson & Johnson (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson Johnson & Johnson (Exact Name of Registrant as Specified in Charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Addr

Exhibit 1.01

Exhibit 1.01 Johnson & Johnson Conflict Minerals Report For the Calendar Year Ended December 31, 2023 Introduction Johnson & Johnson is the parent company of various consolidated subsidiaries (together, the “Company”) engaged in the manufacture and sale of a broad range of Innovative Medicine and MedTech products in the healthcare field. Pursuant to the requirements of Rule 13p-1 under the Securit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Johnson & Johnson (Exact Name of Registrant as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Johnson & Johnson (Exact Name of Registrant as Specified in Its Charter) New Jersey 22-1024240 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) On

KVUE / Kenvue Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Kenvue Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49177J102 (CUSIP Number) May 17, 2024 (Date of Event W

Form of 3.350% Notes due 2036.

EX-4.8 Exhibit 4.8 CUSIP NO.: 478160CZ5 ISIN: XS2821719023 Common Code: 282171902 PRINCIPAL AMOUNT €[      ] REGISTERED NO. R- JOHNSON & JOHNSON 3.350% NOTE DUE 2036 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange

Underwriting Agreement, dated May 14, 2024, among Johnson & Johnson and J.P. Morgan Securities plc, Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and the several Underwriters named therein.

Exhibit 1.3 UNDERWRITING AGREEMENT May 14, 2024 New York, New York Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: J.P. Morgan Securities plc 25 Bank Street, Canary Wharf, London E14 5JP, United Kingdom Citigroup Global Markets Limited Citigroup Centre Canada Square Canary Wharf London E14 5LB United Kingdom Deutsche Bank AG, London Branch 21 Moorfields Lon

Company Order establishing the terms of the Euro Notes.

EX-4.6 Exhibit 4.6 JOHNSON & JOHNSON COMPANY ORDER Pursuant to the authorization of the Board of Directors of Johnson & Johnson, a New Jersey corporation (the “Company”), in resolutions adopted on February 14, 2023, October 31, 2022 and April 25, 2024, the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of the Company, with the te

Company Order establishing the terms of the U.S. Dollar Notes.

Exhibit 4.1 JOHNSON & JOHNSON COMPANY ORDER Pursuant to the authorization of the Board of Directors of Johnson & Johnson, a New Jersey corporation (the “Company”), in resolutions adopted on February 14, 2023, October 31, 2022 and April 25, 2024, the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of the Company, with the terms and

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 31, 2024, pursuant to the provisions of Rule 12d2-2 (a).

Form of 3.200% Notes due 2032.

EX-4.7 Exhibit 4.7 CUSIP NO.: 478160CY8 PRINCIPAL AMOUNT ISIN: XS2821718488 €[       ] Common Code: 282171848 REGISTERED NO. R- JOHNSON & JOHNSON 3.200% NOTE DUE 2032 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange

Form of 3.550% Notes due 2044.

EX-4.9 Exhibit 4.9 CUSIP NO.: 478160DA9 ISIN: XS2821719536 Common Code: 282171953 PRINCIPAL AMOUNT €[      ] REGISTERED NO. R- JOHNSON & JOHNSON 3.550% NOTE DUE 2044 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange

Form of 5.250% Notes due 2054.

EX-4.5 Exhibit 4.5 CUSIP NO. 478160CX0 PRINCIPAL AMOUNT: $[      ] REGISTERED NO. R- JOHNSON & JOHNSON 5.250% NOTE DUE 2054 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CE

Underwriting Agreement Standard Provisions (Debt), dated May 13, 2024.

Exhibit 1.2 JOHNSON & JOHNSON UNDERWRITING AGREEMENT STANDARD PROVISIONS (DEBT) May 13, 2024 From time to time, Johnson & Johnson, a New Jersey corporation (the “Company”), may enter into one or more underwriting agreements (each, an “Underwriting Agreement”) that provide for the sale of designated securities to the several underwriters named therein (the “Underwriters”) arranged by the managers i

Form of 4.800% Notes due 2029.

EX-4.2 Exhibit 4.2 CUSIP NO. 478160CU6 PRINCIPAL AMOUNT: $[      ] REGISTERED NO. R- JOHNSON & JOHNSON 4.800% NOTE DUE 2029 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CE

Form of 4.900% Notes due 2031.

EX-4.3 Exhibit 4.3 CUSIP NO. 478160CV4 PRINCIPAL AMOUNT: $[      ] REGISTERED NO. R- JOHNSON & JOHNSON 4.900% NOTE DUE 2031 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CE

Form of 4.950% Notes due 2034.

EX-4.4 Exhibit 4.4 CUSIP NO. 478160CW2 PRINCIPAL AMOUNT: $[      ] REGISTERED NO. R- JOHNSON & JOHNSON 4.950% NOTE DUE 2034 Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of CE

Underwriting Agreement, dated May 13, 2024, among Johnson & Johnson and J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets Inc., as representatives of the several Underwriters named therein.

EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT May 13, 2024 New York, New York Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 BofA Securities, Inc. One Bryant Park New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: J.P.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Calculation of Filing Fee Tables (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Pr

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be  Paid  Debt  3.

€700,000,000 3.200% Notes due 2032 €800,000,000 3.350% Notes due 2036 €1,000,000,000 3.550% Notes due 2044

Table of Contents Filed Pursuant to Rule 424(b)(2) File number 333-269836 PROSPECTUS SUPPLEMENT (To Prospectus dated February 16, 2023) €700,000,000 3.

Calculation of Filing Fee Tables (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Johnson & Johnson (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed  Maximum  Offering Price  Per Unit  Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Debt  4.

$1,150,000,000 4.800% Notes due 2029 $1,150,000,000 4.900% Notes due 2031 $850,000,000 4.950% Notes due 2034 $850,000,000 5.250% Notes due 2054

Table of Contents Filed Pursuant to Rule 424(b)(2) File number 333-269836 PROSPECTUS SUPPLEMENT (To Prospectus dated February 16, 2023) $1,150,000,000 4.

Pricing Term Sheet Johnson & Johnson 3.200% Notes due 2032 3.350% Notes due 2036 3.550% Notes due 2044 Issuer: Johnson & Johnson Trade Date: May 14, 2024 Expected Settlement Date:* May 20, 2024 (T+4) Format: SEC Registered Security: 3.200% Notes due

FWP Filed Pursuant to Rule 433 Registration No. 333-269836 May 14, 2024 Pricing Term Sheet Johnson & Johnson 3.200% Notes due 2032 3.350% Notes due 2036 3.550% Notes due 2044 Issuer: Johnson & Johnson Trade Date: May 14, 2024 Expected Settlement Date:* May 20, 2024 (T+4) Format: SEC Registered Security: 3.200% Notes due 2032 3.350% Notes due 2036 3.550% Notes due 2044 Size: €700,000,000 €800,000,0

Pricing Term Sheet Johnson & Johnson 4.800% Notes due 2029 4.900% Notes due 2031 4.950% Notes due 2034 5.250% Notes due 2054 Issuer: Johnson & Johnson Security: 4.800% Notes due 2029 4.900% Notes due 2031 4.950% Notes due 2034 5.250% Notes due 2054 S

FWP Filed Pursuant to Rule 433 Registration No. 333-269836 May 13, 2024 Pricing Term Sheet Johnson & Johnson 4.800% Notes due 2029 4.900% Notes due 2031 4.950% Notes due 2034 5.250% Notes due 2054 Issuer: Johnson & Johnson Security: 4.800% Notes due 2029 4.900% Notes due 2031 4.950% Notes due 2034 5.250% Notes due 2054 Size: $1,150,000,000 $1,150,000,000 $850,000,000 $850,000,000 Maturity Date: Ju

Subject to Completion, dated May 14, 2024

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File number 333-269836 The information in this preliminary prospectus supplement is not complete and may be changed.

Subject to Completion, dated May 13, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) File number 333-269836 The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 Johnson & Johnson (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024 ☐ Transition Report Pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact

Johnson & Johnson and Subsidiaries

Exhibit 99.1 Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 21,383 100.0 $ 20,894 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, mark

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Exhibit 99.2 Media contact: [email protected] Investor contact: [email protected] For Immediate Release Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and i

Amended and Restated By-Laws, effective April 25, 2024

Exhibit JOHNSON & JOHNSON AMENDED AND RESTATED BY-LAWS EFFECTIVE: April 25, 2024 ARTICLE I MEETINGS OF SHAREHOLDERS Section 1.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change 2024 2023 Total Operations Currency Sales to customers by segment of business Innovative Medicine (1) U.S. $ 7,612 7,023 8.4 % 8

Exhibit 99.2 Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change 2024 2023 Total Operations Currency Sales to customers by geographic area U.S. $ 11,620 10,782 7.8 % 7.8 — Europe 5,163 5,590 (7.6) (7.7) 0.1 Western Hemisphere excluding U.S. 1,194 1,076 11.0 21.3 (10.3) Asia-Pacific, Africa 3,406 3,446 (1.1) 5.0 (6.1) Internation

Tesia Williams

Exhibit 99.3 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% New Brunswick, NJ (April 16, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly div

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2024 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2024 Johnson & Johnson (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

April 2024

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] Johnson & Johnson Reports Q1 2024 Results •2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* ◦Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* •2024 First-Quarte

April 2024

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] Johnson & Johnson Reports Q1 2024 Results •2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* ◦Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* •2024 First-Quarte

JOHNSON & JOHNSON

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )(1) Contineum Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 21217B100 (CUSIP Number) April 9, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Johnson & Johnson Name of persons relying on exemption: National Legal and Policy Center Address of persons relying on exemption: 107 Park Washington Court, Falls Church, VA 22046 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulg

DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of regis

JOHNSON & JOHNSON STOCK TRADING POLICY FOR DIRECTORS, EXECUTIVE OFFICERS AND INSIDERS

Exhibit 19 JOHNSON & JOHNSON STOCK TRADING POLICY FOR DIRECTORS, EXECUTIVE OFFICERS AND INSIDERS Federal and state laws prohibit Insiders (as defined below) from buying or selling securities of Johnson & Johnson (“J&J”) when they are aware of material non-public information about J&J and from passing along (or “tipping”) such information to others who then trade.

Name of Subsidiary Jurisdiction U.S. Subsidiaries: ABD Holding Company, Inc. Delaware ABIOMED COMMERCIAL, LLC Delaware ABIOMED R&D, Inc. Delaware ABIOMED, Inc. Delaware Acclarent, Inc. Delaware Actelion Pharmaceuticals US, Inc. Delaware Albany Street

EXHIBIT 21 SUBSIDIARIES Johnson & Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of December 31, 2023. Johnson & Johnson is not a subsidiary of any other entity. Name of Subsidiary Jurisdiction U.S. Subsidiaries: ABD Holding Company, Inc. Delaware ABIOMED COMMERCIAL, LLC Delaware ABIOMED R&D, Inc. Delaware ABIOMED, Inc. Delaware Acclarent, Inc. Delawa

JOHNSON & JOHNSON CLAWBACK POLICY

Exhibit 97 JOHNSON & JOHNSON CLAWBACK POLICY The Board of Directors (the “Board”) of Johnson & Johnson (the “Company”) has determined that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company as of the Effective Date.

JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT

Exhibit 10(h) JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT Granted To: John Christian Reed Grant No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

JNJ / Johnson & Johnson / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01257-johnsonjohnson.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Johnson & Johnson Title of Class of Securities: Common Stock CUSIP Number: 478160104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate t

FR:NANO / Nanobiotix S.A. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Nanobiotix S.A. (Name of Issuer) Ordinary Shares, €0.03 nominal value per share (Title of Class of Securities) 63009J107* (CUSIP Number) December 31, 2023

CVRX / CVRx, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 CVRx, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 202

PHGE / BiomX Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 s13ga012224-biomxinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 BiomX Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 09090D103 (CU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

KVUE / Kenvue Inc. / JOHNSON & JOHNSON - SCHWEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Kenvue Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49177J102 (CUSIP Number) December 31, 2023 (Date of Eve

FOURTH QUARTER

Exhibit 99.2 Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FOURTH QUARTER Percent Change 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. $ 12,009 10,820 11.0 % 11.0 — Europe 4,962 5,124 (3.2) (5.8) 2.6 Western Hemisphere excluding U.S. 1,166 1,024 14.0 18.1 (4.1) Asia-Pacific, Africa 3,258 2,971 9.7 12.1 (2.4) Internatio

January 2024

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] Johnson & Johnson Reports Q4 and Full-Year 2023 Results •2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of 10.9%* •2023 Fourt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2024 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Tesia Williams

Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] For immediate release Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review •Provides long-term operational sales outlook, including: oEnterprise Compound Annual Growth Rate (CAGR) of 5-7%1* for 2025-2030 oInnovative Medicine CAGR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Tesia Williams

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] For immediate release Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors New Brunswick, N.J., (November 30, 2023) – Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Execut

Johnson & Johnson MedTech Acquires Laminar, Inc. Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growt

Exhibit 99.1 For immediate release Johnson & Johnson MedTech Acquires Laminar, Inc. Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments NEW BRUNSWICK, N.J. – November 30, 2023 – Johnson & Johnson MedTech1 today announced the complet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2023 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Johnson & Johnson Deferred Compensation Plan

Exhibit 10.1 THE JOHNSON & JOHNSON DEFERRED COMPENSATION PLAN Adopted on November 21, 2023 The Johnson & Johnson Deferred Compensation Plan (the “Plan”) is intended to allow a select group of management and highly compensated employees (as described in Section 201(2) of ERISA) of Johnson & Johnson and its affiliates to defer compensation on an unfunded basis. ARTICLE I - DEFINITIONS Whenever used

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 1, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exac

Exhibit 10.1

EXHIBIT 10.1 CERTIFICATION OF PLAN AMENDMENTS WHEREAS, Johnson & Johnson (the “Company”) sponsors the Johnson & Johnson Excess Savings Plan (the “Plan”); WHEREAS, Section 6.1 of the Plan authorizes the Pension Committee (the “Committee”) to adopt amendments to the Plan on behalf of the Company; and WHEREAS, the Committee wishes to adopt the amendment to the Plan set forth on Exhibit A hereto. NOW,

Exhibit 10.2

EXHIBIT 10.2 Johnson & Johnson Executive Incentive Plan ~ Plan Document ~ (Amended as of September 7, 2023) I. Purpose The purpose of the Johnson & Johnson Executive Incentive Plan (the "Plan") is to attract and retain highly qualified individuals as executive officers; to obtain from each the best possible performance; to underscore the importance to them of achieving particular business objectiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2023 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

###

Media Contacts: Tesia Williams [email protected] Investor Relations: Jessica Moore [email protected] Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech New Brunswick, NJ October 23, 2023 - Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2023 Johnson & Johnson

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

$10.02 – $10.08 / $10.05 12.2% – 12.8% / 12.5%

Exhibit 99.1 Media contact: Tesia Williams [email protected] Investor contact: Jessica Moore [email protected] JOHNSON & JOHNSON REPORTS Q3 2023 RESULTS: •2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%* •Earnings per share (EPS)

THIRD QUARTER

Exhibit 99.2 Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) THIRD QUARTER Percent Change 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. $ 11,996 10,794 11.1 % 11.1 — Europe 4,727 4,844 (2.4) (7.8) 5.4 Western Hemisphere excluding U.S. 1,171 1,059 10.5 12.8 (2.3) Asia-Pacific, Africa 3,457 3,299 4.8 9.4 (4.6) Internationa

Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation

Exhibit 99.1 Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation •Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine •Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00

Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) 2023 Q1 Q2 SIX MONTHS Percent Percent Percent Amount to Sales Amount to Sales Amount to Sales Sales to customers $ 20,89

Exhibit 99.2 Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) FIRST QUARTER Percent Change 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. $ 10,782 9,857 9.4 % 9.4 — Europe 5,590 5,341 4.7 9.4 (4.7) Western Hemisphere excluding U.S. 1,076 998 7.8 15.5 (7.7) Asia-Pacific, Africa 3,446 3,644 (5.4) 3.1 (8.5) International 10,1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023 Johnson & Johnson (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2023 Johnson & Johnson (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Press Release by Johnson & Johnson, dated August 23, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 23, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, par value $1.00 per share (Title of Class of Securities) 478160104 (CUSIP Number of Class of Securities)

Press Release by Johnson & Johnson, dated August 21, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 21, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, par value $1.00 per share (Title of Class of Securities) 478160104 (CUSIP Number of Class of Securities)

Text of the website that is being maintained in connection with the Exchange Offer, updated on August 18, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 18, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on August 16, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 17, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

(incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, par value $1.00 per share (Title of Class of Securities) 478160104 (CUSIP Number of Class of Securities)

, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 17, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

(incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on August 14,

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

connection with the Exchange Offer, updated on August 11, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

the website that is being maintained in connection with the Exchange Offer, updated on August 10, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

the website that is being maintained in connection with the Exchange Offer, updated on August 9, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

the website that is being maintained in connection with the Exchange Offer, updated on August 8, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

the website that is being maintained in connection with the Exchange Offer, updated on August 7, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

the website that is being maintained in connection with the Exchange Offer, updated on August 4, 2023

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Johnson & Johnson and Kenvue Savings Plans Information Agent Talking Points

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, par value $1.00 per share (Title of Class of Securities) 478160104 (CUSIP Number of Class of Securities)

Text of the website that is being maintained in connection with the Exchange Offer, updated on

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on August 2, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 2, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on August 1, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on August 1, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 2, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact n

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 31, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 31, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Consumer Health Separation Shareholder Q&A (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 31, 2023).

jj425-shareholderfaqrefi Consumer Health Separation Shareholder Q&A 1. Why is Kenvue separating from Johnson & Johnson? In November 2021, Johnson & Johnson announced plans to separate its Consumer Health Business. The separation of Kenvue Inc. (“Kenvue”) was a strategic decision made by Johnson & Johnson. Johnson & Johnson believes that the separation will position each company to be more agile, f

Election Forms for Participants in Savings Plans (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 28, 2023).

BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. ATTN: REORGANIZATION DEPARTMENT P.O. BOX 9116 FARMINGDALE, NY 11735-9547 V21186-TBD Box 3 % (insert a percentage in whole numbers, 1% - 99%) I direct State Street to offer to exchange the written percentage of the units attributable my Johnson & Johnson Common Stock Fund account into the Offer. (If you check Box 3 but fail to insert a percentage, your di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: Corporate Secretary Telephone Number: (732) 524-0400

Exhibit 99.1 To: Directors and Executive Officers of Johnson & Johnson Date: July 28, 2023 Subject: Notice of Possible Blackout Period and Regulation BTR Trading Restrictions This blackout notice (“Blackout Notice”) is being provided in order to notify you that directors and executive officers of Johnson & Johnson may be prevented from buying or selling shares of Johnson & Johnson common stock (“J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 28, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 28, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Retiree Portal Webpage Article: Plan for Kenvue Final Separation & Launch of Exchange Offer (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 28, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 Attention: Corporate Secretary Telephone Number: (732) 524-0400

Exhibit 99.1 To: Directors and Executive Officers of Johnson & Johnson Date: July 28, 2023 Subject: Notice of Possible Blackout Period and Regulation BTR Trading Restrictions This blackout notice (“Blackout Notice”) is being provided in order to notify you that directors and executive officers of Johnson & Johnson may be prevented from buying or selling shares of Johnson & Johnson common stock (“J

Kenvue Final Separation & Exchange Offer Launch - Leader Talking Points (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 27, 2023)

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 27, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 27, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 26, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 26, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Consumer Health Separation Shareholder Q&A (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 26, 2023).

jj-425updatedfaq Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

The following is a transcript of a presentation made by Tina Romani, Head of Investor Relations of Kenvue Inc., Thibaut Mongon, Chief Executive Officer of Kenvue Inc., and Paul Ruh, Chief Financial Officer of Kenvue Inc., on www.netroadshow.com in co

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 The following is a transcript of a presentation made by Tina Romani, Head of Investor Relations of Kenvue Inc., Thibaut Mongon, Chief Executive Officer of Kenvue Inc., and Paul Ruh, Chief Financial Officer of Kenvue Inc., on www.netroadshow.com in co

July 2023 Investor Presentation Disclaimer 2 Forward-Looking Statements This presentation contains certain statements about Johnson & Johnson and Kenvue that are forward-looking statements. Forward-looking statements are based on current expectations

kenvue425-roadshowpresen July 2023 Investor Presentation Disclaimer 2 Forward-Looking Statements This presentation contains certain statements about Johnson & Johnson and Kenvue that are forward-looking statements.

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Plan Deadline: 4:00 PM New York City Time, August 15, 2023 IMMEDIATE ATTENTION REQUIRED Dear partici

kenvue425-kenvuesavingsp Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Plan Deadline: 4:00 PM New York City Time, August 15, 2023 IMMEDIATE ATTENTION REQUIRED Dear participant in the Kenvue Savings Plan and/or the Kenvue Retirement Savings Plan: Johnson & Johnson is offering its shareholders the

Communication to Participant in Johnson & Johnson Savings Plan and/or the Johnson & Johnson Retirement Savings Plan (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 25, 2023).

jj425-day2xsavingsplans Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 25, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 25, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Johnson & Johnson Benefit Service Center (“BSC”) (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

1 Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Long-Term Incentive (LTI) Award Treatment at Final Separation for Johnson & Johnson Employees (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023)

jj425-day1xltionepagerwp This document provides information on what is expected to happen to Johnson & Johnson equity compensation (LTI) awards granted under the Johnson & Johnson Long-Term Incentive Plans and held by Johnson & Johnson employees at the final separation.

Filing Fee

Exhibit 107 Calculation of Filing Fee Tables SC TO-I (Form Type) Johnson & Johnson (Name of Issuer) Johnson & Johnson (Name of Person(s) Filing Statement) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $ 39,779,164,791.

Percent Change

Exhibit 99.1 The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the three and six months ended July 3, 2022. Johnson & Johnson has provided certain preliminary results below; however, its closing procedures for

Kenvue Final Separation - Long-Term Incentive (LTI) Awards with PSU (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Leader Update Today, Johnson & Johnson announced its intent to split-off at least 80.1% of the shares of Kenvue Inc. (“Kenvue”) through an exchange offer. As a reminder, Johnson & Johnson currently holds approximately 89.6% of Kenvue’s common stock,

Leader Update Today, Johnson & Johnson announced its intent to split-off at least 80.

Long-Term Incentive Award Treatment at Final Separation for Kenvue Employees (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

jj425-day1xlticonversion This document provides information on what is expected to happen to Johnson & Johnson equity compensation (LTI) awards granted under the Johnson & Johnson Long-Term Incentive Plans and held by Kenvue employees at the final separation.

Communication to Johnson & Johnson Employees: Kenvue Final Separation — Long-Term Incentive (LTI) Awards Update (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

jjltinopsueml Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement SKILLMAN, N.J. July 24, 2023 – Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement tod

Long-Term Incentive (LTI) Award Treatment at Final Separation for Johnson & Johnson Employees (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023)

jj425-day1xltionexpagerw This document provides information on what is expected to happen to Johnson & Johnson equity compensation (LTI) awards granted under the Johnson & Johnson Long-Term Incentive Plans and held by Johnson & Johnson employees at the final separation.

Communication to Johnson & Johnson Employees: Johnson & Johnson Savings Plan and Johnson & Johnson Retirement Savings Plan (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

JOHNSON & JOHNSON SAVINGS PLAN JOHNSON & JOHNSON RETIREMENT SAVINGS PLAN Johnson & Johnson is offering its shareholders the opportunity to exchange shares of Johnson & Johnson common stock for shares of Kenvue Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Perso

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOHNSON & JOHNSON (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, par value $1.00 per share (Title of Class of Securities) 478160104 (CUSIP Number of Class of Securities) Nicholas T. Antoun

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Today, Johnson & Johnson announced its intention to “split off” Kenvue Inc. (“Kenvue”) shares throug

kenvue425-day1prexvueart Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Today, Johnson & Johnson announced its intention to “split off” Kenvue Inc. (“Kenvue”) shares through an exchange offer. Following the completion of our initial public offering (“IPO”) in May, Johnson & Johnson remained Kenvu

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Dear Kenvuers, Today, Johnson & Johnson announced its intent to split-off at least 80.1% of the shar

kenvue425-day1prexallken Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Dear Kenvuers, Today, Johnson & Johnson announced its intent to split-off at least 80.1% of the shares of Kenvue Inc. (“Kenvue”) through an exchange offer. As a reminder, Johnson & Johnson currently holds approximately 89.6%

1 Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Kenvue Benefit Service Center (“BSC”) Talking Points Background On July 24, 2023, Johnson & Johnso

kenvue425-kenvuebenefits 1 Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 Kenvue Benefit Service Center (“BSC”) Talking Points Background On July 24, 2023, Johnson & Johnson announced that it is offering to exchange shares of Kenvue Inc. common stock that it owns for shares of Johnson & Johnson c

Kenvue LTI Final Separation Brochure Cover Note (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Communication to Johnson & Johnson Employees: Plan for Separation of Kenvue & Launch of Exchange Offer (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

jj425-day1prexallemploye Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Press Release by Johnson & Johnson, dated July 24, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Employee Home Webpage Article: Understanding the Exchange Offer (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

jj425-prehomearticleunde Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Consumer Health Separation Shareholder Q&A (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

Text of the website that is being maintained in connection with the Exchange Offer, updated on July 24, 2023 (incorporated by reference to Johnson & Johnson’s Form 425 filing with the SEC on July 24, 2023).

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

KENVUE SAVINGS PLAN KENVUE RETIREMENT SAVINGS PLAN Johnson & Johnson is offering its shareholders the opportunity to exchange shares of Johnson & Johnson common stock for shares of Kenvue Inc. common stock, subject to the terms of the exchange offer

kenvue425-messageonforyo KENVUE SAVINGS PLAN KENVUE RETIREMENT SAVINGS PLAN Johnson & Johnson is offering its shareholders the opportunity to exchange shares of Johnson & Johnson common stock for shares of Kenvue Inc.

***

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2023 Johnson & Johnson (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

The following is an excerpt from Joseph Wolk’s LinkedIn post, published on on July 20, 2023:

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS:

Exhibit 99.1 JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS: •2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* •Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%* •Company is increasing 2023 full-year

The following is an excerpt from Johnson & Johnson’s Second Quarter 2023 Earnings Release, dated July 20, 2023:

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

The following is an excerpt from Johnson & Johnson’s “Johnson & Johnson Reports 2023 Second-Quarter Results” email to employees, delivered on July 20, 2023:

Filed by Johnson & Johnson pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.

SECOND QUARTER

Exhibit 99.2 Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. $ 13,444 12,197 10.2 % 10.2 — Europe 5,894 6,085 (3.1) (3.9) 0.8 Western Hemisphere excluding U.S. 1,713 1,536 11.5 17.7 (6.2) Asia-Pacific, Africa 4,479 4,202 6.6 12.5 (5.9) Internatio

***

Filed by Kenvue Inc. pursuant to rule 425 under the Securities Act of 1933, as amended Subject Company: Johnson & Johnson Commission File No.: 1-3215 The following is an excerpt from Kenvue Inc.’s Second Quarter 2023 Earnings Call Webcast on July 20, 2023: Comments from Thibaut Mongon, Chief Executive Officer and Director: Before we begin, as you may have seen this morning, Johnson & Johnson annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] ANNUAL REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Johnson & Johnson (Exact Name of Registrant as Specified in Charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of Principal E

Exhibit 1.01

Exhibit 1.01 Johnson & Johnson Conflict Minerals Report For the Calendar Year Ended December 31, 2022 Introduction Johnson & Johnson is the parent company of various consolidated subsidiaries (together, the “Company”) engaged in the manufacture and sale of a broad range of products in the health care field across three business segments: Consumer Health, Pharmaceutical and MedTech. Pursuant to the

Employee Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.

EX-10.3 Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023 TABLE OF CONTENTS ARTICLE I Definitions SECTION 1.01. Definitions 1 SECTION 1.02. Glossary of Defined Terms 5 ARTICLE II General SECTION 2.01. Employee Transfers and Wrong Pockets 6 SECTION 2.02. Employees Returning From Leave 6 SECTION 2.03. General Allocation of Employee Liabi

Tax Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.

EX-10.2 Exhibit 10.2 TAX MATTERS AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023 TABLE OF CONTENTS Page ARTICLE I Definitions SECTION 1.01. Definition of Terms 1 ARTICLE II Allocation of Tax Liabilities and Benefits SECTION 2.01. Indemnity by J&J 7 SECTION 2.02. Indemnity by Kenvue 8 SECTION 2.03. Allocation of Ordinary Taxes 8 SECTION 2.04. Allocation of Transfe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 Johnson & Johnson (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Intellectual Property Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.

EX-10.4 Exhibit 10.4 INTELLECTUAL PROPERTY AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS SECTION 1.01. Definitions 1 ARTICLE II TRANSFERRED INTELLECTUAL PROPERTY AND TECHNOLOGY AND ASSUMPTION OF LIABILITIES SECTION 2.01. Assignment of Intellectual Property 11 SECTION 2.02. Common Infrastructure Copyrights 13 SECTION

Registration Rights Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.

EX-10.6 Exhibit 10.6 REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 3, 2023, between Johnson & Johnson, a New Jersey corporation (“J&J”), and Kenvue Inc., a Delaware corporation (the “Company”). WHEREAS the Company intends to offer and sell to the public (the “IPO”), by means of a Registration Statement on Form S-1 (File No. 333-269115) filed with the U.S. Securities and Exchang

Separation Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.

EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023 TABLE OF CONTENTS Page ARTICLE I Definitions SECTION 1.01. Definitions 2 ARTICLE II The Separation SECTION 2.01. Transfer of Assets and Assumption of Liabilities 18 SECTION 2.02. Certain Matters Governed Exclusively by Ancillary Agreements 20 SECTION 2.03. Termination of Intercompany